Combined Therapy of Photoelectric Instruments and Human Umbilical Cord Mesenchymal Stem Cells for Pigmentary Disorders

Launched by SHANGHAI EAST HOSPITAL · Mar 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for melasma, a skin condition that causes brown patches on the face and can affect a person's appearance and confidence. The trial aims to combine two therapies: human umbilical cord mesenchymal stem cells (which are cells that can help repair and regenerate skin) and a specific type of laser treatment. Researchers want to find out if this combined therapy is more effective than using the laser treatment alone.

To participate, women aged 18 to 60 who have been diagnosed with melasma and have stable skin patches for at least three months may be eligible. They should not have had any previous stem cell or laser treatments for this condition. Participants will be divided into three groups: one group will receive both the stem cell infusion and the laser treatment, another group will receive only the stem cell injections with the laser, and the third group will only get the laser treatment. Throughout the study, their skin's improvement will be measured, and their satisfaction with the treatment will be evaluated. This trial is currently not yet recruiting participants, but it represents an exciting step toward finding more effective treatments for melasma.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects must voluntarily participate in this study and sign a written informed consent form.
• • 2. Subjects are female patients with melasma aged between 18 and 60 years. Their diagnosis should conform to the "Chinese Expert Consensus on Diagnosis and Treatment of Melasma (2021 Edition)" formulated by the Pigmentary Disorders Subgroup of the Dermatovenereology Committee of the China Association of Integrative Medicine. The skin lesions manifest as light brown or dark brown patches of varying depths and with indistinct borders on the cheeks, forehead, and jaw. Subjects must be excluded from having post-inflammatory hyperpigmentation, naevus of Ota, Riehl's melanosis, pigmented lichen planus, and other skin diseases. Additionally, their melasma should have been in a stable phase for 3 months or more.
• • 3. Subjects have never undergone stem cell therapy or laser treatment for melasma.
• Exclusion Criteria:
• • 1. Subjects with a history of photosensitivity or allergies to biological medications.
• • 2. Subjects who are pregnant or lactating.
• • 3. Subjects who have a history of alcohol abuse, drug addiction, or substance abuse in the past 24 months.
• • 4. Subjects with concurrent severe systemic diseases, malignancies, or psychiatric disorders.
• • 5. Subjects with active infections, including bacterial, fungal, and viral infections.
• • 6. Subjects with keloid constitution.
• • 7. Subjects with a history of severe sun exposure within 4 weeks before enrollment.
• • 8. Subjects deemed unsuitable for enrollment by the investigator for various reasons or any other conditions that the investigator believes may compromise the safety or compliance of the subject or hinder the successful completion of the study.